Deutsches Krebsforschungszentrum

Ruprecht-Karls-Universitat Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Luxembourg Institute of Health

Marchini, Antonio

Antonio Marchini

Jean Rommelaere

Barbara Leuchs

Nazim El-Andaloussi

Junwei Li

Karsten Geletneky

Michael Dahm

Wolfgang Wick

Assia Angelova

Dirk Jager

Lea Schroeder

Min Li-Weber

Dirk Jäger

Xavier Allaume

Georgi Hristov

Max Endele

Anna Illarionova

Tiina Marttila

Valérie Palissot

Gian Mario Dore

Anna-Paula De-Oliveira

Karen Nieto

Anna Khodosevich

Peter Krammer

The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.

Cancer therapy with a parvovirus combined with a BCL-2 inhibitor

Described are methods for efficiently down regulating the expression of a gene of interest in a cell by use of a modified rodent parvovirus that contains an expressible target specific nucleic acid, preferably an shRNA expression cassette. Also described are cells or organisms comprising said parvovirus.

Modified parvovirus useful for gene silencing

Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor

Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.

Adenovirus derived helper virus for enhancing recombinant parvovirus production

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.

Cancer therapy with a parvovirus combined with an HDAC inhibitor

Described is a chimerical adenovirus-parvovirus vector characterized in that it comprises the entire parvovirus genome inserted into a adenovirus genome, wherein: (a) the adenovirus genome is characterized by deletion of E1 and E3, and (b) the biological activity of the parvoviral protein NS, preferably NS1, is reduced or eliminated.

Adeno-parvovirus chimera with enhanced oncolytical potential

Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.

Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of its capsid

Growing community of inventors

Heidelberg, Germany

Antonio Marchini